Evidence map›Paper›PMID 42527520›Full record

ArticleCell death and differentiation2026

Dual targeting of BCL-XL and MCL-1 exposes a rapid and exploitable apoptotic vulnerability in non-small cell lung cancer.

Liyang Wu, Baris Budak, Oihane Ofogo, Ali Jazaeri Jouneghani, Philippe JeanRichard, Daniel Bachmann, Thomas Kaufmann

Abstract read
PubMed Publisher
In one paragraph

Article in Cell death and differentiation, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Liyang WuInstitute of Pharmacology, University of Bern, Inselspital, INO-F, Bern, Switzerland.ORCID http://orcid.org/0000-0001-6930-1993
Baris BudakInstitute of Pharmacology, University of Bern, Inselspital, INO-F, Bern, Switzerland.
Oihane OfogoInstitute of Pharmacology, University of Bern, Inselspital, INO-F, Bern, Switzerland.
Ali Jazaeri JouneghaniInstitute of Pharmacology, University of Bern, Inselspital, INO-F, Bern, Switzerland.
Philippe JeanRichardInstitute of Pharmacology, University of Bern, Inselspital, INO-F, Bern, Switzerland.ORCID http://orcid.org/0009-0004-9005-1211
Daniel BachmannInstitute of Pharmacology, University of Bern, Inselspital, INO-F, Bern, Switzerland.ORCID http://orcid.org/0009-0002-6635-7312
Thomas KaufmannInstitute of Pharmacology, University of Bern, Inselspital, INO-F, Bern, Switzerland. thomas.kaufmann@unibe.ch.ORCID http://orcid.org/0000-0001-9906-874X

Funding

Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung (Swiss National Science Foundation) 310030_201199
6 · The paper itself

Abstract

Non-small cell lung cancer (NSCLC) is frequently refractory to mitochondrial apoptosis despite oncogenic and therapeutic stress. Although individual anti-apoptotic BCL-2 family members have been implicated in NSCLC survival, it has remained unclear whether this reflects dominant single-protein dependencies or a cooperative pro-survival network. This uncertainty is exacerbated by the high prevalence of p53 mutations, which compromise DNA damage-induced apoptotic signaling. Here, we systematically dissected intrinsic apoptotic dependencies across a panel of human NSCLC cell lines using selective BH3 mimetics targeting BCL-2, BCL-XL or MCL-1. Consistent with previous reports, BH3 mimetics alone provided only limited and heterogeneous sensitization to cisplatin across NSCLC models. Likewise, single-agent inhibition of BCL-2, BCL-XL or MCL-1 elicited weak and variable apoptotic responses. In striking contrast, combined targeting of BCL-XL and MCL-1 was sufficient to trigger rapid, synergistic and irreversible apoptosis in the majority of NSCLC cell lines, even in the absence of genotoxic stress. Commitment to cell death occurred within minutes and was characterized by early mitochondrial outer membrane permeabilization, cytochrome c release and robust effector caspase activation. This apoptotic response strictly required the intrinsic mitochondrial machinery and BAX/BAK function but was entirely independent of p53 status. Apparent resistance to first-generation (WEHI-539) BCL-XL inhibition in a subset of models reflected incomplete target engagement rather than compensatory survival rewiring. Accordingly, apoptosis was fully restored by next-generation BCL-XL inhibition (A-1331852) or by PROTAC-mediated BCL-XL degradation (DT2216). Importantly, platelet-sparing BCL-XL targeting strategies retained strong synergy with MCL-1 inhibition, addressing a key translational limitation of earlier BH3-mimetic approaches. Together, these data redefine apoptotic control in NSCLC as a cooperative restraint imposed by BCL-XL and MCL-1 rather than discrete, context-dependent dependencies, revealing a rapid, p53-independent mitochondrial apoptotic vulnerability with clear therapeutic implications.

Identifiers

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.